Lilly basal bests Lantus in T1D, despite safety concerns

Share this article:
Eli Lilly
Lilly basal bests Lantus in T1D, despite safety concerns

Eli Lilly may not need to pin its hopes on Basaglar, the generic version of Sanofi's Lantus which is now in marketing limbo, after all. The Indianapolis drugmaker unveiled new data today that shows its basal insulin peglispro significantly lowered HbA1c in type 1 diabetics compared to Lantus and another entrenched product. Peglispro is the first drug of its kind to demonstrate superior HbA1c reduction versus Lantus in Phase-III trials, according to Lilly.

In those Phase-III trials—IMAGINE-1 and IMAGINE-3—peglispro demonstrated “consistent superiority” in HbA1c tests against Lilly's own Humalog and Lantus at the 26- and 52-week period. Based on this data, Lilly expects to send the data over to US and EU regulators by the end of Q1 2015.

That submission could help shore up a spot for Lilly between two long-acting insulin heavyweights in Lantus and Novo Nordisk's Levemir. The market for insulins that last longer in the body is one of the most contested diabetes treatment sectors right now. For the first half of 2014, Levemir saw $1.2 billion in worldwide sales while Lantus brought in $3.8 billion.

While this may represent a billion-dollar opportunity for Lilly, peglispro is not without its faults. In trials, patients taking peglispro showed a “small, but statistically significant,” increase in triglycerides, liver enzymes and blood pressure. Those numbers may not tell the whole story however, as “there were no major adverse cardiac events,” or “cases of severe liver injury,” in either trial.

Earlier this year, Sanofi sued Lilly for patent infringement, delaying Basaglar (formerly known as LY2963016) from coming to market for as much as 30 months. The legal tactic bought Sanofi more time to work on its successor to $6 billion/year Lantus—known as U300—but while U300 remains under wraps until later this year, peglispro could eat into that lucrative pie.

Meanwhile, Merck has initiated Phase-III studies for MK-1293, a drug meant to be very similar to Lantus. The drugmaker announced a partnership earlier this year with Samsung Biopes (Samsung and Biogen Idec collaboration) to develop and commercialize it.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...